Humacyte rustles up $12 million and a new chief executive

MedCity News logo

Duke University spin-off Humacyte Inc. landed a $12 million investment and pharmaceutical industry veteran Carrie Cox for CEO.

The Durham, N.C.-based regenerative medicine company recently raised $12 million from a single investor through a debt offering, according to an amended filing with the Securities & Exchange Commission. Another amended filing shows the company raised $7 million in debt about a year ago.

Humacyte founder and former CEO Dr. Laura Niklason would say only that “we have taken in funds from our existing investors,” when asked by the Triangle Business Journal about the recent investments and their purposes.

Humacyte uses a proprietary technology to engineer human tissues that can be shaped into tubes, sheets and other forms to treat vascular diseases and repair the body. Niklason, a former Duke researcher, started the company in late 2004 to use human cells to make artificial blood vessels that could be transplanted into patients suffering from kidney failure and other ailments, the Triangle Business Journal said.

Cox, who had been executive vice president and president of Global Pharmaceuticals at Schering-Plough Corp., will assumer her new role on Sept. 20, according to Humacyte. She is expected to lead the young Research Triangle Park company from its development to its commercialization phase.

“We are clearly delighted to have an executive with the experience, leadership and sound business judgment of Carrie Cox to lead Humacyte at this important juncture in our company’s history,” Niklason said in prepared remarks. “Carrie is ideally qualified to oversee our ongoing product development efforts and lead us into commercialization of these much-needed treatment options for patients.”

Cox left Schering-Plough with a golden parachute estimated at between $36 million and $44 million when her company was acquired by Merck & Co. in November 2009, according to a pharmaceutical industry blog. That doesn’t include about $11 million in net gains from exercising Schering-Plough stock options in April and May of 2007 — before the release of disappointing study results on the company’s Vytorin cholesterol-lowering drug.

Those stock option sales are part of an ongoing class-action shareholder lawsuit that alleges securities misdeeds by Schering-Plough executives. Some posts at a CafePharma message board on the topic were submitted as evidence in the case. In June, a federal district court judge upheld an August 2009 decision to deny defendants’ request to dismiss the case.

In December, Cox signed on as a director of drug distributor Cardinal Health, Ohio’s largest corporation. Fortune Magazine has named Cox to its list of the 50 Most Powerful Women in Business six times, according to Cardinal and Humacyte.

“I am proud to join Humacyte and become part of creating the future of regenerative medicine,” Cox said in the release. “The breakthrough science being conducted at Humacyte may one day bring major benefits to patients, while also improving health outcomes and reducing costs.”

RSS From Medical Design & Outsourcing

  • 3-phase current transducer from PEM delivers all-in-one convenience
    The new RCTrms 3-ph current transducer from Power Electronic Measurements (PEM) delivers a convenient, safe and accurate solution for measuring current in three phases. It features a thin, clip-around, flexible sensor coil and provides accurate true rms measurement with 4-20 mA or 0-5 V output, enabling simple installation with PLC’s, SCADA systems or automation equipment. […]
  • Safety alert: Recall on two IV solutions from Baxter
    Baxter International announced it is voluntarily recalling two lots of intravenous (IV) solutions to the hospital and user level due to the potential presence of particulate matter. The particulate matter in each case was determined to be an insect and was identified as a result of a customer complaint. The matter was identified prior to […]
  • TSO3 begins shipment of STERIZONE VP4 Sterilizers to U.S.
    TSO3, a developer in sterilization technology for medical devices in healthcare settings, announced that the company has received purchase orders for multiple devices from the U.S. The orders are the result of the collaborative relationship between Getinge Infection Control, its sales and service provider, and TSO3. “Finally,” said R.M. Rumble, president and CEO of TSO3. “Our Vision is […]
  • Turkish medical company is seeking reseller and OEM partners in the U.S.
    UZUMCU Medical Equipment, one of Turkey’s first and largest manufacturers of medical devices, is seeking reseller and OEM partners in the U.S. The company has an array of FDA-certified OR tables, surgical lights, surgical suction units, electro devices and other medical equipment. “We want to bring our experience with distributors throughout Europe and the Middle […]
  • QImaging introduces new CCD cameras for microscopy with modern software to streamline image capture
    QImaging, a manufacturer of scientific cameras for life science and OEM applications, introduces a new series of Retiga CCD cameras, accompanied by QImaging’s new acquisition software to deliver high-performance tools for microscopy and imaging to researchers at an affordable price. The new QImaging Retiga R1, Retiga R3 and Retiga R6 cameras offer valuable technical features […]
  • Sigma-Aldrich announces a new certification to aid IVD customers
    Sigma-Aldrich, a life science and high technology company, announced the company has received ISO 13485 certification for expanded quality assurance capabilities at its Dekalb and Barton facilities located in St. Louis. The certification extends Sigma-Aldrich’s ability to manufacture and offer critical raw materials, such as enzymes, proteins and antibodies used in diagnostic assays, and supplies in vitro […]
  • Prescribing the right power supply: Important considerations for using batteries to power medical devices
    Sol Jacobs, VP and General Manager, Tadiran Batteries Medical technology is advancing rapidly, requiring increasingly sophisticated power management solutions, especially when then the device needs to be self-powered. Battery-powered medical devices encompass a wide range of applications, including surgical drills, power tools, automatic external defibrillators (AEDs), infusion pumps, bone growth stimulators and other wearable devices, […]
  • Qosina announces the launch of its e-commerce website
    Qosina is pleased to announce the launch of its e-commerce website, making it easier to purchase thousands of medical device components from stock inventory. Visitors coming to the new Qosina.com will discover a new look and feel and improvements with every click including: · Easy navigation: A new category structure that mirrors the print catalog […]
  • Athermal laser machining for medical implants is the topic of Norman Noble’s latest whitepaper
    Thermal lasers have achieved extraordinary results in microprecision manufacturing of medical implants and devices the past 20 years. Devices we take for granted today, such as vascular stents, could not be produced without the technology; however, there are still significant limitations on what medical implant and device manufactures can produce using thermal lasers. One major issue […]
  • Sealevel announces the SeaISO family of USB isolators
    Sealevel announces the SeaISO family of USB isolators with 4 kV of medical-grade optical isolation between the host computer and connected USB equipment. SeaISO USB isolators are UL Recognized, in accordance with EN60601-1 3rd Edition, and protect both the power and data lines of connected USB devices from harmful ground loops, damaging transients and surges […]
  • The 21st Century Cures Discussion document recently released to the public
    It has been reported that among the 10,000 known diseases, 7,000 of which are considered rare, there are treatments for only 500. According to Dr. Francis Collins, Director of the National Institutes of Health (NIH), it now takes “around 14 years and $2 billion or more” to develop a new drug and “more than 95% […]

Leave a Reply